GlassScriptPhysician profile
Alan Kalischer
NPI 1598727299
$2,302.22
in general payments reported to CMS, 2019-2025
21 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $257 · 2021: $372 · 2022: $328 · 2023: $378 · 2024: $328 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $578.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $323.17 | 2021-2025 | Verquvo |
| Amgen INC. | $237.74 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $181.67 | 2021-2025 | Mitraclip, Aveir |
| Sanofi-Aventis U.S. LLC | $164.21 | 2019-2024 | |
| Pfizer INC. | $152.43 | 2020-2024 | |
| Esperion Therapeutics, INC. | $141.30 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $127.37 | 2019-2021 | |
| Boston Scientific Corporation | $77.43 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $53.65 | 2019-2023 | Xarelto |
| G Medical Diagnostic Services, INC. | $53.61 | 2019-2023 | Cardiac Monitoring Suite |
| Edwards Lifesciences Corporation | $42.14 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $37.24 | 2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $36.98 | 2022-2023 | |
| Novo Nordisk INC | $15.53 | 2025 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $14.97 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2019 | |
| Vital Connect, INC | $13.81 | 2025 | Vitalpatch Rtm |
| Sun Pharmaceutical Industries INC. | $13.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.43 | 2019 | |
| Cvrx, INC. | $11.30 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kalischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.